Skip to main content
TipRanks
Go Ultimate75% OFF

Enliven Therapeutics (ELVN) Stock Price & Analysis

355 Followers

ELVN Stock Chart & Stats

$46.53$0.12(0.26%)
At close: 4:00 PM EST
$40$50$60Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$45.64 - $47.83
52-Week Range
$14.79 - $62.32
Previous Close
$46.41
Volume
N/A
Average Volume (3M)
1.39M
Market Cap
$3.42B
Enterprise Value
$2.69B
Total Cash (Recent Filing)
$884.35M
Total Debt (Recent Filing)
$1.31M
Price to Earnings (P/E)
―
Beta
0.68
Next Earnings
Mar 18, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Balance Sheet

Substantial and growing equity combined with minimal debt gives Enliven financial flexibility to fund clinical development without heavy leverage. This capitalization reduces refinancing pressure and supports continued investment while the company works toward potential commercialization.

Extended Clinical Runway

A cash runway extending into 2030 provides time to advance relcobatinib through pivotal development without immediate funding pressure. FDA alignment on ENABLE-2 also creates a clearer regulatory and execution path for the company’s first pivotal trial.

Experienced Governance

Adding an experienced biopharmaceutical executive to the board strengthens governance and financial oversight as Enliven moves toward late-stage development. Her background guiding biotech companies toward commercial operations may support execution and future launch planning.

Bears Say

No Commercial Revenue

Enliven has not yet established commercial revenue, leaving its financial profile dependent on successful clinical progress and eventual product approval. Persistent losses also mean current operations are not self-funding, limiting earnings visibility over the next several quarters.

Persistent Cash Burn

Sustained negative operating and free cash flow consumes the resources available for research and trials, even with a strong balance sheet. Continued burn raises the importance of disciplined spending and successful development milestones before the company can generate internal cash.

Clinical-stage Execution Exposure

Because Enliven remains focused on clinical development, its long-term business outcome depends on advancing candidates through trials and establishing therapeutic value. Until those programs mature, the company has limited operating diversification and remains exposed to development execution.

Enliven Therapeutics News

ELVN FAQ

What was Enliven Therapeutics’s price range in the past 12 months?
Enliven Therapeutics lowest stock price was $14.79 and its highest was $62.32 in the past 12 months.
What is Enliven Therapeutics’s market cap?
Enliven Therapeutics’s market cap is $3.42B.
When is Enliven Therapeutics’s upcoming earnings report date?
Enliven Therapeutics’s next earnings report is estimated for Mar 18, 2027 (not yet confirmed), which is in 117 days.
How were Enliven Therapeutics’s earnings last quarter?
Enliven Therapeutics released its earnings results on Nov 05, 2026. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.448 by $0.088.
Is Enliven Therapeutics overvalued?
According to Wall Street analysts Enliven Therapeutics’s price is currently Undervalued.
Does Enliven Therapeutics pay dividends?
Enliven Therapeutics does not currently pay dividends.
What is Enliven Therapeutics’s EPS estimate?
Enliven Therapeutics’s EPS estimate is -0.44.
How many shares outstanding does Enliven Therapeutics have?
Enliven Therapeutics has 73,595,130 shares outstanding.
What happened to Enliven Therapeutics’s price movement after its last earnings report?
Enliven Therapeutics reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.448. Following the earnings report the stock price went up 10.359%.
Which hedge fund is a major shareholder of Enliven Therapeutics?
Hedge funds hold Enliven Therapeutics shares: the largest hedge-fund position in Enliven Therapeutics is 72,324,914 shares, and hedge funds increased their holdings by 936.2K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology